2. Academic Validation
  3. Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro

Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro

  • PeerJ. 2023 Jan 25;11:e14610. doi: 10.7717/peerj.14610.
Xinyue Wang # 1,  Songyi Qian # 2,  Siyi Wang 1,  Sheng Jia 1,  Nishang Zheng 1,  Qing Yao 1,  Jian Gao 3
Affiliations

Affiliations

  • 1 Department of Nutrition, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
  • 2 Department of Cardiac Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
  • 3 Department of Nutrition, Zhongshan Hospital, Fudan University, Shanghai, China.
  • # Contributed equally.
PMID: 36718449 DOI: 10.7717/peerj.14610
Abstract

Lenvatinib has become a first-line drug in the treatment of advanced hepatocellular carcinoma (HCC). Investigating its use in combination with other agents is of great significance to improve the sensitivity and durable response of Lenvatinib in advanced HCC patients. Vitamin C (L-ascorbic acid, ascorbate, VC) is an important natural antioxidant, which has been reported to show suppressive effects in Cancer treatment. Here, we investigated the effect of the combination of VC and Lenvatinib in HCC cells in vitro. We found that treatment of VC alone significantly inhibited the proliferation, migration and invasion in HCC cells. Additionally, VC was strongly synergistic with Lenvatinib in inhibition of the proliferative, migratory and invasive capacities of HCC cells in vitro. In conclusion, our results demonstrate that the combination of VC and Lenvatinib has synergistic antitumor activities against HCC cells, providing a promising therapeutic strategy to improve the prognosis of HCC patients.

Keywords

Invasion; Lenvatinib; Migration; Proliferation; Vitamin C.

Figures
Products